Psilocybin aids 180‑day cocaine abstinence

Cocaine addiction is one of those disorders medicine has never really cracked. People relapse a lot, overdose deaths keep climbing, and there still is not an approved medication for cocaine use disorder. That is the gap this new trial was trying to hit. A team at the University of Alabama at Birmingham just published a randomized study showing that one supervised psilocybin session, wrapped in structured psychotherapy, improved abstinence outcomes for 6 months. ### What actually happened in the trial? This was a small but real randomized clinical trial — not an anecdote, not an open-label pilot. Forty adults with cocaine use disorder were assigned 1:1 to either a single oral dose of psilocybin or an active placebo, diphenhydramine, with both groups getting the same manualized psychotherapy built around cognitive behavioral treatment. Recruitment ran from May 2015 to August 2023, and follow-up finished in May 2024. (jamanetwork.com) ### Why use psilocybin here at all? The basic idea is that addiction is not just a chemical dependence problem. It is also rigid behavior, craving, avoidance, and a kind of mental tunnel vision. Psilocybin researchers think the drug may temporarily loosen those patterns, making therapy more effective if the setting is controlled and the patient is prepared. That is why the treatment was not “take a mushroom and go home.” It was one dosing day plus about a month of therapy before and after. (jamanetwork.com) ### What were the headline results? The headline number is the one people are circulating — 30% of participants in the psilocybin group achieved complete cocaine abstinence through 180 days after treatment, while none in the placebo group did. The psilocybin group also had a higher percentage of cocaine-abstinent days overall and a longer time before first lapse. In plain English, more people stopped, and the people who did lapse tended to lapse later. (jamanetwork.com) ### Was this just self-reporting? Not entirely. The researchers tracked use with timeline followback interviews and confirmed abstinence with urinalysis. Thirty-six participants completed the 180-day assessment. That does not erase every measurement problem — addiction trials are messy by nature — but it is stronger than simply asking people how they think they did months later. ### Who was in the study? (jamanetwork.com) The sample matters here. Most participants were Black men around age 50, and most had annual incomes of $20,000 or less. That is notable because psychedelic trials have often skewed whiter and wealthier than the populations most affected by addiction. So even though the study was small, it was not just another highly filtered wellness-clinic sample. ### What is the catch? (jamanetwork.com) The catch is scale. Forty people is tiny. The lead author also served as the primary therapist, which makes standardization harder. And psychedelic trials have a blinding problem — people can often guess whether they got the real drug. So this is promising evidence, but not the kind that settles practice on its own. ### Why does this matter beyond one study? (jamanetwork.com) Because cocaine use disorder has been a graveyard for medications. A big 2021 meta-analysis of 157 trials found that contingency management — basically structured rewards for abstinence — was the only treatment consistently linked to negative cocaine tests, while no pharmacotherapy was approved in the US or Europe. This psilocybin result does not change the standard of care yet, but it does open a genuinely new lane. (uab.edu) ### So what should people take from this? The useful takeaway is not that psilocybin is now a proven cocaine treatment. It is that a serious controlled study finally produced a signal strong enough to justify larger trials. If those replicate, this could become one of the first medication-assisted approaches that actually moves the needle for cocaine addiction. (jamanetwork.com 1) (jamanetwork.com 2)